Truism that "nothing sells itself" combined with "Doctors listen to their peers" makes me skeptical of GSK turning reps into some lowly version of an MSL. Seems like GSK is seeking a PC way to eliminate the current structure of pay & bonus to a promotional sales force as they downsize the sales group. More important to me as an investor that this is a red-flag about GSK's pipeline. Going to be interesting what the "work-grounds" will be. Remember ZS Assocs. only get paid to help rearrange the chairs on the Titanic.
Still can't get over the image from the funeral.
The one with the black guy standing there, fooling the whole world
into thinking he knew what he was doing!
When he really was a fraud, a phony!
AND then there was also the fake sign language guy!
quiet now, don't roar about GLW too much, allow us all to accumulate and let them all wonder why & how come I didn't as GLW keeps taking positive steps. Let them all be distracted about what the Fed will do while we keep to our financial goals.
I am surprised that no one commented on T. Boone Pickens' comments this morning with the business talking heads about CMI. Not worried about foreign business but, rather, ability to build enuff NatGas engines for the US long-haul trucking demand anticipated.
In my experience: the short term sales may climb even as you whack the sales force. Let's assume 80/20 so the reduction eliminated 20% low performers (not fair as they are compared to what?) you still got rid of another 30% productive reps. That impact will start to be felt, typically, around the 6 month mark as the remaining sales force wears down from trying to do more with less. The real impact of the sales force whack usually means the incline of the new script starts is lessened and opportunities lost as the "plane" is flatter. Hope that makes a modicum of sense. One can't deny momentum has been lost which is unfortunate for the company, the shareholders, and the patients who could benefit.
Ain't it a hairball to have to announce a Phase3 15,000 patient trial (highly conservative min of $2000 per patient or $30,000,000) FAILURE to hit the primary end-points? Makes one wonder what the 2nd Phase3 of 13,000 patients ACS trial will tell the medical community that the first doesn't? Just what questions are trying to be answered?
Makes no sense risk/reward after buying Epanova. Let someone else do the proof to final question of positive CDV effect to lowering TGs. Better question is why does the FDA, with it's current stance, allow any fish oil (OTC or Rx) to make unproven CDV health claims? AMRN is the whipping boy for the entire category!!!
Ironic the AHA says great to use to lower TGs yet the FDA'$ AdCom says huh? Should have the Cardiologists review instead of the childish metabolic docs.....
I agree going down the path of FDA negotiation but the challenge is how subtle is the disease to show positive changes? As you know, the size and length of the study is needed to get statistically sig results. By opening early, one may be screwing the pooch on the final results. FDA should give them the Anchor indication only with the commitment necessary to finish REXUCE-IT, IMO. Otherwise, they may force the throwing the baby out with the bathwater?
Nah, but it is a tougher climb up over a "wall of worry" than it is to fall off the wall so all the King's men can't....
Chill dude, if you are convinced then this is an opportunity dip to take advantage. Enjoy a 32 oz soda on Bloomberg